Publicacions (42) Publicacions de Alfonso Garcia De Coca

2024

  1. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

2022

  1. TRAF3 alterations are frequent in del-3′IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features

    American Journal of Hematology, Vol. 97, Núm. 7, pp. 903-914

2021

  1. Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420

  2. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

2020

  1. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications

    International Journal of Cancer, Vol. 147, Núm. 10, pp. 2780-2792

  2. Integrated genomic analysis of chromosomal alterations and mutations in B-cell acute lymphoblastic leukemia reveals distinct genetic profiles at relapse

    Diagnostics, Vol. 10, Núm. 7

2019

  1. CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase

    Leukemia, Vol. 33, Núm. 2, pp. 518-558

  2. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

2018

  1. Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study

    Annals of Hematology, Vol. 97, Núm. 3, pp. 475-484

2017

  1. Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  2. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma

    Haematologica, Vol. 102, Núm. 5, pp. 922-931

2016

  1. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma

    Leukemia, Vol. 30, Núm. 10, pp. 2026-2031

  2. MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion

    Leukemia Research, Vol. 46, pp. 30-36

  3. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

  4. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

    Blood, Vol. 127, Núm. 24, pp. 3035-3039

  5. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab

    British journal of haematology, Vol. 172, Núm. 3, pp. 428-438

2015

  1. MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL

    BMC Cancer, Vol. 15, Núm. 1

  2. Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions

    Transfusion, Vol. 55, Núm. 7, pp. 1745-1751

  3. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

    Leukemia

  4. The cellular origin and malignant transformation of Waldenström macroglobulinemia

    Blood, Vol. 125, Núm. 15, pp. 2370-2380